Pfizer’s (PFE-$18.85) anti-HIV drug Selzentry is now approved for combination use with other antiretroviral agents for treatment-naïve patients infected with CCR5-tropic HIV-1. Granted accelerated approval by the FDA in August 2007 for treatment-experienced patients infected with the R5 HIV-1 strain, industry pundits forecasted sales of more than $500 million by 2012. Uptake of Selzentry by HIV specialists has been less than expected — a marketing disaster — with Pfizer reporting paltry sales of just $46 million in 2008.
Will expanded labeling lead to usage beyond salvage therapy for this entry inhibitor? Read More at BNET Pharma….
Will expanded labeling lead to usage beyond salvage therapy for this entry inhibitor? Read More at BNET Pharma….
Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.
No comments:
Post a Comment